Pilot study to validate a computer-based clinical decision support system for dyslipidemia treatment (HTE-DLP)

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 401-404

  Zamora, A ^a,b,c   Fernandez De Bobadilla F ^d   Carrion, C ^a   Vazquez G ^e   Paluzie, G ^e   Elosua, R ^c   Vilaseca, M ^e   Martin Urda A ^f   Rivera, A ^b   Plana, N ^g,m   Masana, L ^g   Cruz, Almendros Mari ^f   Thais, Bosch ^h   Cristina, Campoamor ⁱ   Ferrán, Cordón ^j   Rafa, Cuenca ⁱ   Gemma, Estrada ^k   Monserrat, García Cors ^l   Carlos, Sevilla Juan ^f   Miquel, Sillero ⁱ   Cristina, Soler ^m   Roser, Valverde ⁿ   more..

^a UNIVERSITY OF GIRONA   (Spain)

^b Hospital de Blanes   (Spain)

^c Heracles Cardiovascular Network   (Spain)

^d Empresa Pública Desarrollo Agrario y Pesquero   (Spain)

^e Corporació de Salut del Maresme I la Selva ^*  (Spain)

^f Hospital de Palamos   (Spain)

^g HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^h Hospital de Puigerdá   (Spain)

ⁱ Hospital de Calella   (Spain)

^j CAP Montillivi   (Spain)

^k CAP Malgrat   (Spain)

^l HOSPITAL GENERAL DE CATALUNYA   (Spain)

^m Hospital de Santa Caterina   (Spain)

ⁿ CAP Palafolls   (Spain)

more..

Author keywords

CDSS; Computerized decision support system; Hyperlipidemia

Indexed keywords

ATORVASTATIN; EZETIMIBE; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; COMPUTERIZED DECISION SUPPORT SYSTEM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; TREATMENT DURATION;

CDSS; COMPUTERIZED DECISION SUPPORT SYSTEM; HYPERLIPIDEMIA;

AGED; ATHEROSCLEROSIS; CARDIOLOGY; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DECISION SUPPORT SYSTEMS, CLINICAL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERVENTION STUDIES; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; TRIGLYCERIDES; USER-COMPUTER INTERFACE;

EID: 84888080505     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.09.029     Document Type: Article

References (21)

1. Dégano I.R., Elosua R., Marrugat J. Epidemiology of acute coronary syndromes in Spain: estimation of the number of cases and trends from 2005 to 2049. Rev Esp Cardiol 2013, 66:472-481.
2. Baigent C., Keech A., Kearney P.M., et al. Cholesterol treatment trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
3. Baena-Díez J.M., Félix F.J., Grau M., et al. Risk factor treatment and control in relation to coronary disease risk in the Spanish population of the DARIOS Study. Rev Esp Cardiol 2011, 64:766-773.
4. García Ruiz F.J., Marín Ibáñez A., Pérez-Jiménez F., et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmacoeconomics 2004, 22(Suppl.3):1-12. REALITY Study Group.
5. Masana L., Plana N. Objective-oriented planification in the treatment of hypercholesterolemia. Med Clin (Barc) 2005, 124:108-110.
6. Roshanov P.S., Misra S., Gerstein H.C., et al. Computerized clinical decision support systems for chronic disease management: a decision-maker-researcher partnership systematic review. Implement Sci 2011, 6:92. CCDSS Systematic Review Team.
7. Siskind A., Johnson M., Qureshi A., Solow B., Chesebro D., Oldham N. The impact of automatic prescriptions on reducing low-density lipoprotein cholesterol levels. Eff Clin Pract 2000, 3:240-246.
8. Chen C., Chen K., Hsu C.Y., Chiu W.T., Li Y.C. Aguideline-based decision support for pharmacological treatment can improve the quality of hyperlipidemia management. Comput Methods Programs Biomed 2010, 97:280-285.
9. Main C., Moxham T., Wyatt J.C., Kay J., Anderson R., Stein K. Computerised decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems. Health Technol Assess 2010 Oct, 14(48):1-227.
10. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423.
11. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818. European Association for Cardiovascular Prevention & Rehabilitation.
12. Van Wyk J.T., van Wijk M.A., Sturkenboom M.C., Mosseveld M., Moorman P.W., van der Lei J. Electronic alerts versus on-demand decision support to improve dyslipidemia treatment: a cluster randomized controlled trial. Circulation 2008, 117:371-378.
13. Bertoni A.G., Bonds D.E., Chen H., et al. Impact of a multifaceted intervention on cholesterol management in primary care practices: guideline adherence for heart health randomized trial. Arch Intern Med 2009, 169:678-686.
14. Rosenberger E.L., Goff D.C., Blackwell C.S., et al. Implementing a palm pilot intervention for primary care providers: lessons learned. Contemp Clin Trials 2009, 30:321-325.
15. Gilutz H., Novack L., Shvartzman P., et al. Computerized community cholesterol control (4C): meeting the challenge of secondary prevention. Isr Med Assoc J 2009, 11:23-29.
16. Lester W.T., Grant R.W., Barnett G.O., Chueh H.C. Randomized controlled trial of an informatics-based intervention to increase statin prescription for secondary prevention of coronary disease. JGen Intern Med 2006, 21:22-29.
17. Katz P.M., Mendelsohn A.A., Goodman S.G., Langer A., Teoh H., Leiter L.A. Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk guideline-based undertaking to improve dyslipidemia management in Canada (GUIDANC). Can J Cardiol 2011, 27:138-145.
18. Bełtowski J., Wójcicka G., Jamroz-Wiśniewska A. Adverse effects of statins-mechanisms and consequences. Curr Drug Saf 2009, 4:209-228.
19. Shah S., Ceska R., Gil-Extremera B., et al. Efficacy and safety of extended-release niacin/laropiprant plus statin vs doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2010, 64:727-738.
20. Michelis K.C., Hassouna B., Owlia M., Kelahan L., Young H.A., Choi B.G. Effect of electronic prescription on attainment of cholesterol goals. Clin Cardiol 2011, 34:254-260.
21. Tan Woan Shin, Phang Jonathan SK., Tan Lay Kheng Evaluating user satisfaction with an electronic prescription system in a primary care group. Ann Acad Med Singapore 2009, 38:494-500.